NEW YORK, Aug. 10 Reportlinker.com announces that a new market research report is available in its catalogue:
Hormone Replacement Therapy in Menopause - Pipeline Assessment and Market Forecasts to 2017
Advertisement
http://www.reportlinker.com/p0254468/Hormone-Replacement-Therapy-in-Menopause---Pipeline-Assessment-and-Market-Forecasts-to-2017.html
Hormone Replacement Therapy in Menopause - Pipeline Assessment and Market Forecasts to 2017
Advertisement
Summary
GlobalData's has released its pharmaceutical and healthcare report, "Hormone Replacement Therapy in Menopause - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global menopause hormone therapy market. The report identifies the key trends shaping and driving the global menopause hormone therapy market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global menopause hormone therapy sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts. GlobalData estimated the global hormone therapy (HT) market to be worth $2.4 billion in 2009, indicating a Compound Annual Growth Rate (CAGR) of -5.9% between 2001 and 2009. This decline in the market is mainly attributed to poor patient compliance as a result of the serious safety concerns associated with hormones. By 2017, the market is forecast to be worth $2.8 billion, with a CAGR of 2.2% between 2009 and 2017. The market is restrained by factors such as the poor acceptance of hormone therapies in patients and physicians. Increased interest in low-dose and ultra-low dose hormone therapies are expected to lead to marginal growth of the HT market.
Scope
The report provides information on the key drivers and challenges in the menopause hormone therapy market. Its Scope includes:
- Annualized global menopause hormone therapy market revenues data from 2001 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. These drugs are estrogens or progestins (including combination therapies and low-dose therapies), non-hormonal products such as serum estrogen receptor modulators, serotonin reuptake inhibitors, estrogen receptor alpha agonists, among others.
- Analysis of the current and future competition in the global menopause hormone therapy market. The key market players covered are Pfizer, Merck & Co, Amgen, BioSante Pharmaceuticals, Noven Pharmaceuticals, Bionovo, QuatRx Pharmaceuticals and Depomed.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for the hormone replacement therapy market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global menopause hormone therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global menopause hormone therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global menopause hormone therapy market landscape? - Identify, understand and capitalize.
Table of Contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Hormone Replacement Therapeutics: Introduction 6
2.1 GlobalData Pipeline Report Guidance 7
2.2 Concerns Raised Regarding the Safety of Hormone Therapy 8
2.2.1 WHI study 8
2.2.2 Million Women Study 8
2.2.3 Heart and Estrogen/Progestin Replacement Study (HERS) 9
2.2.4 Women's Angiographic Vitamin and Estrogen (WAVE trial) 9
2.2.5 Women's Estrogen-Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial (WELLHART trial) 9
2.2.6 Estrogen Replacement and Atherosclerosis (ERA) study 10
2.2.7 WHI Memory Study (WHIMS study) 10
2.2.8 Postmenopausal Estrogen/Progestin Interventions (PEPI) study 10
2.2.9 Scientific Evidence and Perceptions about the Safety and Efficacy of Hormone Therapy 10
2.2.10 Conclusion 12
2.3 Hormone Replacement Therapy Market Size 13
2.4 Hormone Replacement Therapy Market Forecast and CAGR 13
2.5 Drivers and Barriers for the Hormone Replacement Therapy Market 15
2.5.1 Drivers for the Hormone Replacement Therapy Market 15
2.5.2 Restraints for the Hormone Replacement Therapy Market 15
2.6 Opportunity and Unmet Need 16
2.7 Key Takeaway 17
3 Hormone Replacement Therapy Market: Competitive Assessment 18
3.1 Overview 18
3.2 Strategic Competitor Assessment 18
3.3 Product Profile for the Major Marketed and Off-label Products in the Hormone Therapy Market 19
3.3.1 Enjuvia (synthetic conjugated estrogens, B) 19
3.3.2 Femtrace (estradiol acetate) 21
3.3.3 Premarin (conjugated estrogens) 22
3.3.4 Estrace (estradiol) 24
3.3.5 Femring (estradiol acetate vaginal ring) 25
3.3.6 Vagifem (estradiol vaginal tablets) 27
3.3.7 Transdermal and Topical Estrogen Therapy Products for Postmenopausal Use 28
3.3.8 Menostar (estradiol transdermal) 28
3.3.9 Mirena (levonorgestrel-releasing intrauterine system) 30
3.3.10 Prochieve (Progesterone gel) 30
3.3.11 Prempro (Conjugated Estrogens/ Medroxyprogesterone Acetate Tablets) 31
3.4 Key Takeaway 33
4 Hormone Therapy Market: Pipeline Assessment 34
4.1 Overview 34
4.2 Strategic Pipeline Assessment 34
4.2.1 Technology Trends Analytic Framework 34
4.3 Hormone Therapy - Promising Drugs under Clinical Development 36
4.4 Molecule Profile for Promising Drugs under Clinical Development 37
4.4.1 Aprela (Bazedoxifene/Conjugated Estrogen) 37
4.4.2 Serada (Gabapentin, DM-5689) 38
4.4.3 Odanacatib (MK-0822) 38
4.4.4 Ophena (Ospemifene) 39
4.4.5 ALX1-11 (PREOS, parathyroid hormone 1-84 [rDNA origin] injection) 40
4.4.6 Menerba (MF-101) 41
4.4.7 Pristiq (Desvenlaxafine, DVS-233) 42
4.4.8 Mesafem (low-dose paroxetine mesylate) 43
4.4.9 LibiGel (Testosterone gel) 43
4.5 Hormone Therapy Market - Clinical Pipeline by Mechanism of Action 44
4.6 Hormone Therapy Pipeline - Pipeline by Phase of Clinical Development 45
4.6.1 Hormone Therapy - Phase III Pipeline 46
4.6.2 Hormone Therapy - Phase II Pipeline 47
4.6.3 Hormone Therapy - Phase I Pipeline 48
4.6.4 Hormone Therapy - Preclinical Pipeline 49
4.6.5 Hormone Therapy - Discovery Pipeline 50
4.7 Discontinued / Suspended Drugs for Hormone Replacement Therapy 50
4.8 Key Takeaway 51
5 Hormone Replacement Therapeutics Market: Implications for Future Market Competition 52
6 Hormone Therapy Market: Future Players in Hormone Therapy Market 54
6.1 Introduction 54
6.2 Pfizer 54
6.2.1 Company Overview 54
6.2.2 Business Description 55
6.2.3 Hormone Therapeutics Portfolio 56
6.3 Merck & Co. 57
6.3.1 Company Overview 57
6.3.2 Business Description 57
6.3.3 Hormone Therapeutics Portfolio 58
6.4 Amgen 58
6.4.1 Company Overview 58
6.4.2 Business Description 59
6.4.3 Hormone Therapeutics Portfolio 60
6.5 BioSante Pharmaceuticals 60
6.5.1 Company Overview 60
6.5.2 Business Description 60
6.5.3 Hormone Therapeutics Portfolio 61
6.6 Noven Pharmaceuticals 61
6.6.1 Company Overview 61
6.6.2 Business Description 61
6.6.3 Hormone Therapeutics Portfolio 62
6.7 Bionovo, Inc. 62
6.7.1 Company Overview 62
6.7.2 Business Description 62
6.7.3 Hormone Therapeutics Portfolio 63
6.8 QuatRx Pharmaceuticals Company 63
6.8.1 Company Overview 63
6.8.2 Hormone Therapeutics Portfolio 64
6.9 Depomed Inc. 64
6.9.1 Company Overview 64
6.9.2 Business Description 64
6.9.3 Hormone Therapeutics Portfolio 65
7 Hormone Therapeutics Market: Appendix 66
7.1 Definitions 66
7.2 Acronyms 66
7.3 Scope of Pipeline Research 68
7.4 Research Methodology 68
7.4.1 Coverage 69
7.4.2 Secondary Research 69
7.4.3 Forecasting 69
7.4.4 Primary Research 72
7.4.5 Expert Panel validation 72
7.5 Contact Us 72
7.6 Disclaimer 72
7.7 Sources 73
List of Tables
1.1 List of Tables
Table 1: Hormone Therapeutics, Global, Market Revenue ($bn), 2001-2009 13
Table 2: Hormone Therapeutics, Global, Market Forecast ($bn), 2009-2017 14
Table 3: Hormone Replacement Therapy, Most Promising Drugs Under Clinical Development, 2010 36
Table 4: Hormone Therapeutics, Global, Osteoporosis, Phase III Pipeline, 2010 46
Table 5: Hormone Therapeutics, Menopause, Global, Phase III Pipeline, 2010 46
Table 6: Hormone Therapeutics, Osteoporosis, Global, Phase II Clinical Pipeline, 2010 47
Table 7: Hormone Therapeutics, Menopause, Global, Phase II Clinical Pipeline, 2010 47
Table 8: Hormone Therapeutics, Osteoporosis, Global, Phase I Clinical Pipeline, 2010 48
Table 9: Hormone Therapeutics, Menopause, Global, Phase I Clinical Pipeline, 2010 48
Table 10: Hormone Therapeutics, Osteoporosis, Global, Preclinical Pipeline, 2010 49
Table 11: Hormone Therapeutics, Menopause, Global, Preclinical Pipeline, 2010 49
Table 12: Hormone Therapeutics, Osteoporosis, Global, Discovery Pipeline, 2010 50
Table 13: Hormone Therapy, Global, Discontinued Drugs, 2010 50
Table 14: Hormone Therapeutics, Global, Pfizer Pipeline Drugs, 2010 56
Table 15: Hormone Therapeutics, Global, Merck & Co. Pipeline Drugs, 2010 58
Table 16: Hormone Therapeutics, Global, Amgen Pipeline, 2010 60
Table 17: Hormone Therapeutics, Global, BioSante Pipeline, 2010 61
Table 18: Hormone Therapeutics, Global, Noven Pipeline, 2010 62
Table 19: Hormone Therapeutics, Global, Bionovo Pipeline, 2010 63
Table 20: Hormone Therapeutics, Global, QuatRx Pipeline, 2010 64
Table 21: Hormone Therapeutics, Global, Depomed Pipeline, 2010 65
List of Figures
1.2 List of Figures
Figure 1: Hormone Therapeutics, Global, Market Revenue ($bn), 2001-2009 13
Figure 2: Hormone Therapeutics, Global, Market Forecast ($bn), 2009-2017 14
Figure 3: Opportunity and Unmet Need, Hormone Replacement Therapy, 2010 16
Figure 4: Strategic Competitor Assessment of Major Marketed Products, Hormone Therapy, 2010 19
Figure 5: Hormone Therapy, Menopause, Technology Trends Analytic Framework , 2010 34
Figure 6: Hormone Therapy, Menopause, Technology Trends Analytic Framework - Description , 2010 35
Figure 7: Hormone Therapy Market - Clinical Pipeline by Mechanism of Action, 2010 45
Figure 8: Hormone Therapy, Global, Pipeline by Phases of Clinical Development, 2010 45
Figure 9: Implications for Future Market Competition in the Hormone Therapy Market, 2010 52
Figure 10: Hormone Therapy Market, Global, Clinical Pipeline by Company, 2010 54
Figure 11: GlobalData Methodology, 2010 68
Figure 12: GlobalData Market Forecasting Model, 2010 71
To order this report:
Pharmaceutical Industry: Hormone Replacement Therapy in Menopause - Pipeline Assessment and Market Forecasts to 2017
Pharmaceutical Business News
More Market Research Report
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)-652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
